Pathological and clinical impact of neoadjuvant chemoradiotherapy using full‐dose gemcitabine and concurrent radiation for resectable pancreatic cancer

Abstract

Our current protocol of neoadjuvant chemoradiotherapy is feasible and substantially improves the pathology. However, it has some detrimental effects on postoperative nutritional status and performance of adjuvant chemotherapy. Furthermore, it should be noted that there is a possibility of arterial complications.